GBIO vs AVDL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (3โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GBIO counters with relative strength in Valuation. Fundamentally, GBIO trades at 7.9x Forward P/E with -2020.0% operating margin (-78.9% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, GBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | GBIO | AVDL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $38.7M | $2.1B | Larger Scale | AVDL |
| Trailing P/E Ratio Valuation | 7.9x | 16.8x | Lower Multiple | GBIO |
| Forward P/E Ratio Valuation | 7.9x | 28.8x | Lower Multiple | GBIO |
| Revenue Growth (YoY) Growth | -78.9% | +54.9% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | -2020.0% | 2.5% | Higher Margin | AVDL |
| Net Profit Margin Profitability | 0.0% | -0.1% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -80.8% | -0.3% | Higher ROE | AVDL |
| 52-Week Range Position Momentum | 62% ($0โ$8) | 89% ($6โ$24) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 0.80ฮฒ ยท 26% Vol | 0.14ฮฒ ยท 2% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 58.8 / 100 (HOLD) | 62.9 / 100 (BUY) | Higher Composite | AVDL |